Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics at an average price of $491.57, generating approximately $4.67 million and reducing her stake by 2.84%.
- United Therapeutics beat quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, but revenue fell 1.9% year over year and missed estimates at $783.3 million.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $621, while institutional investors own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $491.57, for a total transaction of $4,669,915.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $159,486,445.51. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
United Therapeutics Stock Down 3.5%
Shares of UTHR stock opened at $472.21 on Friday. The stock's 50-day moving average price is $512.06 and its 200 day moving average price is $540.50. United Therapeutics Corporation has a 52-week low of $409.07 and a 52-week high of $609.35. The stock has a market capitalization of $20.25 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the company posted $6.41 earnings per share. The company's revenue for the quarter was down 1.9% compared to the same quarter last year. Analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on UTHR shares. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Finally, Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $621.00.
Read Our Latest Analysis on UTHR
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of UTHR. Callan Family Office LLC purchased a new position in United Therapeutics during the second quarter worth about $1,217,000. Nicholas Investment Partners LP increased its position in shares of United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after acquiring an additional 3,766 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics during the 2nd quarter valued at $3,359,000. Havemeyer Place LP purchased a new stake in United Therapeutics during the 4th quarter worth $2,189,000. Finally, Seven Fleet Capital Management LP purchased a new position in United Therapeutics in the fourth quarter valued at about $633,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
More United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics is using the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. The reduced share count could support earnings per share and provide some underlying demand for the stock. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
- Neutral Sentiment: The company’s prior quarter showed better-than-expected earnings, but revenue declined year over year and fell short of estimates. This leaves investors focused on whether newer products can offset pressure on the established pulmonary-hypertension franchise.
- Negative Sentiment: Goldman Sachs initiated coverage with a Sell rating and a $321 price target, arguing that UTHR trades above its long-term valuation range. The call was a significant negative catalyst because it implies substantial downside from recent trading levels. United Therapeutics, Sagimet drop after Goldman issues Sell ratings
- Negative Sentiment: Goldman also highlighted risks involving payer and reimbursement dynamics, potential generic competition, and uncertain real-world adoption of Jenraldi, a newer growth driver. Investors remain concerned that broader coverage requirements for nebulized Tyvaso could limit future revenue growth. United Therapeutics Slips as New Sell Rating Pressures Shares
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her position by 2.84%. The sale may add to sentiment concerns, particularly alongside reports that company insiders have made numerous sales and no purchases recently, although the transaction could also reflect routine personal or tax-related activity. SEC insider transaction filing
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
